Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.42 |
| ▸ | IDH1 | O75874 | 2/20 | 0.40 |
| ▸ | IDH2 | P48735 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2890958 | 0.89 | GPR119 (0.44) | GPR119ESR2NR1H2PIK3CAMAPK1 | |
| SCHEMBL2889110 | 0.82 | ESR2 (0.40) | GPR119ESR2NR1H2DDB1CRBN | |
| SCHEMBL2883228 | 0.81 | ESR2 (0.40) | GPR119ESR2NR1H2DDB1CRBN | |
| SCHEMBL2883231 | 0.81 | ESR2 (0.40) | GPR119ESR2NR1H2DDB1CRBN | |
| SCHEMBL2883177 | 0.81 | ESR2 (0.40) | GPR119ESR2NR1H2DDB1CRBN | |
| SCHEMBL2883230 | 0.81 | ESR2 (0.40) | GPR119ESR2NR1H2DDB1CRBN | |
| SCHEMBL2888850 | 0.81 | ESR2 (0.41) | GPR119ESR2NR1H2DDB1CRBN | |
| SCHEMBL2887295 | 0.80 | ESR2 (0.44) | GPR119ESR2NR1H2PIK3CAMAPK1 | |
| SCHEMBL2889334 | 0.80 | ESR2 (0.44) | ESR2NR1H2PIK3CAMAPK1MTOR | |
| SCHEMBL2886944 | 0.80 | ACACB (0.42) | GPR119ESR2NR1H2PIK3CAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2213675-B1 | PYRIDOOXAZEPINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-8329687-B2 | Pyridooxazepine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100286120-A1 | PYRIDOOXAZEPINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-2213675-A1 | PYRIDOOXAZEPINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286120-A1 | PYRIDOOXAZEPINE DERIVATIVE AND USE THEREOF | HTR2C, HTR2A, TPH2 | GPR119 568/4885IDH1 3266/4885IDH2 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.